(Bloomberg) In July 2014, Dimitry Khmelnitsky advised investors to sell Valeant Pharmaceuticals International Inc. and then watched the stock double in a year.“It was very painful,” Khmelnitsky, an analyst at Veritas Investment Research Corp., said in an telephone interview from his office in Toronto. “What I felt was pain.”
The Lone Analyst Who Said Sell Valeant When Hedge Funds Piled In
This entry was posted in Syndicated. Bookmark the permalink.
